Learn new advances in the treatment of relapsed or refractory immune thrombocytopenia, including treatment differentiation, efficacy and safety strategies, and much more. This activity features perspectives from two noted experts in the field, Dr. Keith McCrae, Director of Benign Hematology at the Cleveland Clinic Taussig Cancer Center; and Ms. Phyllis McKiernan, Advanced Practice Nurse, John Theurer Cancer Center, Hackensack Meridian Health.

Studies have shown that certain cancer therapies adversely affect the heart and lead to various types of injuries, which often result in death. This activity reviews recent advances in the management of cancer teatment-induced cardiotoxicity.

This episode of Oncology Data Advisor^TM will focus on advances in the treatment of relapsed or refractory immune thrombocytopenia. It features perspectives from two noted experts in the field: Dr. Keith McCrae, Director of Benign Hematology at the Cleveland Clinic Taussig Cancer Center; and Ms. Phyllis McKiernan, Advanced Practice Nurse, John Theurer Cancer Center, Hackensack Meridian Health.